

1 **CD16a<sup>high</sup> NK cell infiltration and spatial relationships with T cells and macrophages can**  
2 **predict improved progression-free survival in high grade ovarian cancer**

3 Sarah Nersesian, MSc<sup>1</sup> ([s.nersesian@dal.ca](mailto:s.nersesian@dal.ca)), Stacey N. Lee<sup>1</sup> ([stacey.lee@dal.ca](mailto:stacey.lee@dal.ca)), Stephanie

4 Grantham<sup>1</sup> ([stephanie.grantham@dal.ca](mailto:stephanie.grantham@dal.ca)), Liliane Meunier<sup>2</sup>

5 ([liliane.meunier.chum@ssss.gouv.qc.ca](mailto:liliane.meunier.chum@ssss.gouv.qc.ca)), Laudine Communal<sup>2</sup>

6 ([laudine.eve.desreumaux@umontreal.ca](mailto:laudine.eve.desreumaux@umontreal.ca)), Thomas Arnason, MD<sup>4</sup>

7 ([thomas.arnason@nshealth.ca](mailto:thomas.arnason@nshealth.ca)), Dirk Arnold, PhD<sup>5</sup> ([dirk@cs.dal.ca](mailto:dirk@cs.dal.ca)), Brad H. Nelson, PhD<sup>6,7,8</sup>

8 ([bnelson@bccrc.ca](mailto:bnelson@bccrc.ca)), Anne-Marie Mes-Messon, PhD, FCAHS, FRSC<sup>2,3</sup> ([9 \[masson@umontreal.ca\]\(mailto:masson@umontreal.ca\)\), Jeanette E. Boudreau, PhD\\*<sup>1,4</sup> \(\[jeanette.boudreau@dal.ca\]\(mailto:jeanette.boudreau@dal.ca\)\)](mailto:anne-marie.mes-</a></p></div><div data-bbox=)

10 <sup>1</sup>Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada

11 <sup>2</sup>Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de

12 Montréal, Québec, Canada

13 <sup>3</sup>Department of Medicine, Université de Montréal, Montreal, Quebec, Canada

14 <sup>4</sup>Department of Pathology, Dalhousie University, Halifax, NS, Canada

15 <sup>5</sup>Department of Computer Science, Dalhousie University, Halifax, NS, Canada

16 <sup>6</sup>Deeley Research Centre, British Columbia Cancer Agency, Victoria, BC, Canada

17 <sup>7</sup>Department of Biochemistry and Microbiology, University of Victoria, BC, Canada

18 <sup>8</sup>Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada

19 **\*Corresponding Author:** Dr. Jeanette Boudreau, 15-F2 5850 College St., Halifax, NS, Canada

20 B3H 4R5 [jeanette.boudreau@dal.ca](mailto:jeanette.boudreau@dal.ca)

21 **Word count:** 4978

22 **Keywords:** High grade serous carcinoma, ovarian cancer, natural killer cell, tumor infiltrating

23 lymphocytes, multiplex immunohistochemistry, spatial pathology, quantitative

24 immunohistochemistry, NK cells

25

26

27 **ABSTRACT**

28 **Background:** High grade serous cancer (HGSC) remains a highly fatal malignancy with less than  
29 50% of patients surviving 5 years after diagnosis. Despite its high mutational burden, HGSC is  
30 relatively refractory to checkpoint immunotherapy, suggesting that additional features of the  
31 cancer and its interactions with the immune system remain to be understood. Natural killer (NK)  
32 cells may contribute to HGSC control, but the role(s) of this population or its subsets in this disease  
33 are poorly understood.

34 **Methods:** We used a TMA containing duplicate treatment-naïve tumors from 1145 patients with  
35 HGSC and a custom staining panel to simultaneously measure macrophages, T cells and NK cells,  
36 separating NK cells based on CD16a expression. Using pathologist-validated digital pathology,  
37 machine learning, computational analysis and Pearson’s correlations, we quantitated infiltrating  
38 immune cell density, co-infiltration and co-localization with spatial resolution to tumor region. We  
39 compared the prognostic value of innate, general, and adaptive immune cell “neighborhoods” to  
40 define characteristics of HGSC tumors predictive for progression-free survival and used flow  
41 cytometry to define additional features of the CD16a<sup>dim</sup> NK cell subset.

42 **Results:** NK cells were observed in >95% of tumor cores. Intrastromal localization of CD16a<sup>low</sup>  
43 and CD16a<sup>high</sup> NK cells was associated with shorter and longer progression-free survival,  
44 respectively. CD16a<sup>high</sup> NK cells most frequently co-localized with T cells and macrophages; their  
45 proximity was termed an “adaptive” neighborhood. We find that tumors with more area  
46 represented by adaptive immune cell neighborhoods corresponded to superior progression free  
47 survival. In contrast, CD16a<sup>low</sup> NK cells did not co-infiltrate with other immune cell types, and  
48 expressed the ectonucleotidases, CD39 and CD73, which have been previously associated with  
49 poor prognosis in patients with HGSC.

50 **Conclusions:** Progression-free survival for patients with HGSC may be predicted by the subset of  
51 NK cells within the tumor infiltrate (i.e. CD16a<sup>high</sup> vs. CD16a<sup>low</sup>). NK cell subtypes were  
52 associated predictable co-infiltrating and co-localizing leukocyte subsets, suggesting that their  
53 presence and activity may influence, or be influenced by the tumor microenvironment. Our data  
54 suggest that immunotherapeutic strategies for HGSC should consider the constitution of NK cell  
55 subsets and may benefit from mobilizing and activating CD16<sup>high</sup> NK cells.

56

## 57 BACKGROUND

58 High grade serous carcinomas (HGSC) are the most common, aggressive and genetically unstable  
59 form of ovarian cancer, and associated with the poorest 5-year survival rate[1, 2]. A lack of  
60 effective screening methods and specific signs and symptoms typically leads to late-stage  
61 diagnosis, when patients frequently have metastatic disease (80%, stage III or IV)[1, 2]. Although  
62 tumors initially respond to a combination of platinum and taxane based chemotherapy, over 70%  
63 recur, most as chemotherapy resistant[2, 3]. Despite a high mutational burden and consequently  
64 high neoantigen load, anti-PD-L1 therapies have been largely ineffective against HGSC (overall  
65 response rate 0-11.5%)[4-6]. Perhaps the dynamic nature of the tumor, and loss of human  
66 leukocyte antigen (HLA) expression challenges the generation and efficacy of anti-tumor (HLA-  
67 restricted) T cell responses[7, 8]. Collaboration from other immune cell types, including natural  
68 killer (NK) cells could extend immune reactivity against HGSC; these cells have not been as  
69 extensively studied.

70 NK cells comprise approximately 10% of circulating cells and were first defined based on  
71 their antitumor potential[9]. NK cells differentiate from the common lymphoid progenitor in the  
72 bone marrow and are most closely related to T cells with similar features for cytokine production  
73 and cytotoxicity of target cells. The potent anti-tumor capability of NK cells is antigen-  
74 independent[10-12]. NK cells can be broadly categorized into two main populations based on  
75 CD16a and CD56 expression[10]. CD56<sup>bright</sup>/CD16a<sup>low</sup> NK cells primarily produce cytokines, such  
76 as IFN- $\gamma$ , TNF and GM-CSF[13]. CD56<sup>dim</sup>/CD16a<sup>high</sup> NK cells can also produce these cytokines,  
77 and additionally are the primary cytotoxic effectors, through expulsion of perforin and granzymes,  
78 or via the Fas and TRAIL death-receptor pathways[10, 14]. NK cells exhibit an array of  
79 phenotypes and related functions, which are governed by variable expression and co-expression

80 of germline-encoded receptors[15]. The functions of NK cells are diverse, ranging from missing  
81 self-reactivity (an ability to kill cells based on loss of self HLA), induced-self reactivity (killing  
82 cells with over-expression of stress-associated ligands), antibody-dependent cellular cytotoxicity  
83 and immunoregulation[16, 17].

84 Despite significant suppression within the tumor microenvironment (TME) and relatively  
85 low numbers of NK cells infiltrating tumors, two studies conducted with a small number of HGSC  
86 core biopsies (<300 patients) found infiltrating NK (CD57<sup>+</sup>) cells to be associated with improved  
87 clinical outcomes[18, 19]. Interestingly, these associations were strengthened when considering  
88 NK cells in the intraepithelial (IE) region of the tumor[18, 19]. This is particularly relevant given  
89 that NK cells existing within the cancer cell nest (IE region) express increased levels of inhibitory  
90 receptors, including NKG2A, compared to those in the stromal region, suggesting a higher  
91 propensity for inhibition compared to activation[20]. These studies provide the important proof-  
92 of-concept that NK cell infiltration is associated with beneficial outcomes clinically, but CD57 is  
93 only expressed on a relatively mature subset of NK cells and therefore may not accurately represent  
94 the entire NK cell population[18, 21-23]. To enable analysis of the *entire* infiltrating NK cell  
95 population, we designed and validated a multiplex panel for precise NK cell identification in  
96 HGSC by combining antibodies against CD16a (NK cells, macrophages), CD94 (a component of  
97 the binding complexes formed by the NK receptor group 2 (NKG2) receptors present in some form  
98 on all NK cells, T cells), CD3 (T cells) and CD68 (macrophages and mononuclear phagocytes)  
99 and pancytokeratin[24, 25]. With this panel, we find that NK cells infiltrated the majority of HGSC  
100 cores, but we observed subtype specific patterns: CD16a<sup>low</sup> NK cells typically infiltrated alone,  
101 while CD16a<sup>high</sup> NK cells more often co-infiltrated with T cells and macrophages. This latter  
102 “adaptive” group was associated with improved progression-free survival among patients with

103 HGSC, while a relative enrichment for “innate” CD16a<sup>low</sup> areas was associated with shorter  
104 progression free survival time. CD16a<sup>high</sup> NK cell infiltration was further associated with stage 4  
105 and grade 3 tumors, and adaptive neighborhoods were more often found in tumors harboring  
106 *BRCA1/2* mutations. CD16a<sup>low</sup> NK cells correspond with CD39/73 expression, and were  
107 associated with features of immunoregulation and poorer prognosis. Taken together, our findings  
108 underscore a positive prognostic impact of CD16<sup>high</sup> NK cells, and support strategies to maximize  
109 the antitumor activities of this population in patients with HGSC.

110

## 111 **METHODS**

### 112 **Patients and Tumor Microarrays**

113 We conducted multiplex immunofluorescence staining followed by quantitative analysis on a  
114 formalin-fixed paraffin-embedded (FFPE) HGSC tumor microarray (TMA). The TMA slides were  
115 obtained after scientific review from the COEUR (The Canadian Ovarian Experimental Unified  
116 Resource) committee. Patient samples were collected from 12 Canadian ovarian cancer biobanks,  
117 from 1992 to 2014, and detailed patient demographics and tumor characteristics have been  
118 published previously[26]. The COEUR TMA consists of duplicate core tumors isolated from 1159  
119 patients with HGSC. Following tissue staining, image processing, and pathologist review (detailed  
120 below), 1145 patients were analyzed. All methods for specimens and clinical information  
121 collection and subsequent analyses were approved by Dalhousie University's Research Ethics  
122 Board (#2020-5060). The use of primary peripheral blood mononuclear cells (PBMC) to validate  
123 antibodies were approved by the Dalhousie University REB (#2016-3842) and the Canadian Blood  
124 Services REB (#2016-016) and collected in collaboration with the Canadian Blood Services  
125 Blood4Research program.

126

### 127 **OPAL Multiplex Immunofluorescence**

128 Our multiplex immunofluorescence protocol was established in accordance with the Society for  
129 Immunotherapy of Cancer's best practices for multiplex immunohistochemistry and  
130 immunofluorescence staining and validation[27]. TMA slides were de-paraffinized, rehydrated,  
131 and then fixed in 10% neutral buffered formalin for 25 minutes. Antigen retrieval was conducted  
132 by microwave treatment (2 minutes at 100% power followed by 15 minutes at 20% power, 1000W  
133 microwave) in Tris-EDTA buffer (pH 9). Slides were then cooled for 15 minutes at room

134 temperature, rinsed with deionized water, then with Tris-Buffered Saline and Tween 20 (TBST)  
135 buffer. The tyramide signal amplification (TSA)-based IF staining protocol was conducted  
136 according to the Opal 7-colour manual IHC kit (Akoya Bio, cat#NEL811001KT). Slides were  
137 incubated in blocking buffer for 10 minutes (Akoya Bio) to stabilize epitopes and reduce  
138 background staining). Slides were then incubated with selected primary antibody (summarized  
139 below) for 45 minutes, rinsed in TBST, and incubated with secondary anti-mouse and anti-rabbit  
140 HRP (Akoya Bio) for 10 minutes. Fluorophore staining was then conducted with a selected Opal  
141 fluorophore in Opal amplification diluent (Akoya Bio, cat#FP1498). The slides were then rinsed  
142 and underwent second microwave treatment to remove the previous antibody. Steps were  
143 sequentially repeated for each antibody in the multiplex panel (Supplementary Table 2). The order  
144 of antibody staining was optimized empirically, and generally occurred in the order from most to  
145 least frequent epitope in the panel (Supplementary Table 2). Following the staining of the last  
146 antibody, slides were incubated with Spectral DAPI (Akoya Bio) for 5 minutes, rinsed and  
147 mounted in Prolong Gold mounting media (Invitrogen). Cell surface specific antibody binding  
148 patterns were validated by a pathologist (TA) (Supplementary Figure 2).

149

### 150 **Multispectral Analysis and Automated Quantitative Pathology**

151 Images were captured using a Mantra 2 Quantitative Pathology Workstation (Akoya Bio), at 20x  
152 magnification, with multispectral separation capabilities at 10 nm wavelength intervals from  
153 420 nm to 740 nm. Images were then visualized and processed in InForm Tissue Finder Software  
154 (Akoya Bio, cat#CLS135783) to conduct multispectral analysis (extracting fluorescent signatures)  
155 and subsequent quantitative pathology. Monoplex stains were used to calibrate spectral imaging,  
156 creating a spectral reference library, as described by manufacturer's instructions (Akoya Bio).

157 Following spectral unmixing, tissues were segmented based on cytokeratin staining and  
158 autofluorescence to define regions as tumor epithelia, tumor stroma, vasculature/autofluorescence  
159 or off the tumor core. This was followed by cellular segmentation which identified individual  
160 nuclei based on DAPI staining. Each cell was then assigned a unique cell ID which was used to  
161 quantify the antibody signal surrounding the individual nuclei. These antibody signatures were  
162 used to phenotype cells into epithelial cells (PanCK<sup>+</sup>CD<sup>-</sup>), stromal cells (PanCK<sup>-</sup>CD<sup>-</sup>), CD16a<sup>high</sup>  
163 NK cells (CD16a<sup>high</sup>CD94<sup>+/-</sup>CD68<sup>-</sup>CD3<sup>-</sup>), CD16a<sup>low</sup> NK cells (CD16a<sup>low</sup>CD94<sup>+</sup>CD68<sup>-</sup>CD3<sup>-</sup>), T  
164 cells (CD3<sup>+</sup>), Macrophages (CD68<sup>+</sup>) or strongly auto-fluorescent red blood cells (PanCK<sup>-</sup>CD<sup>-</sup>  
165 Autofluorescent<sup>++</sup>). All digital scoring and quantification were validated by TA (Supplementary  
166 Figure 3). Consistency between cores were also assessed and validated (Supplementary Figure 4).

167

## 168 **Data Processing**

169 Data were organized and processed through phenoptR Reports in R Studio. Cell segmentation  
170 phenotyping data from 2318 cores were exported as a summary of each phenotype density  
171 (cells/mm<sup>2</sup>). Of the 2318 cores, 15 (0.65%) were lost during tissue processing and/or staining, 56  
172 (2.4%) and 9 (0.39%) cores were excluded because they did not reach our pre-determined requisite  
173 threshold of 1000 cells/mm<sup>2</sup> in their epithelial and stromal compartments respectively. Excluded  
174 cores represented a total of six patients. When our algorithm reported cell counts >1.5 interquartile  
175 ranges above the third, or below the first quartile, they were manually reviewed. These outliers  
176 included 52 (2.24%) CD3<sup>+</sup>, 8 (0.34%) CD68<sup>+</sup>, 67 (2.9%) CD16a<sup>high</sup> and 76 (3.3%) CD16a<sup>low</sup>  
177 cores. Of these, 83 (3.6%) were identified to have artifacts, intrusive autofluorescence or  
178 unspecific staining leading to incorrect phenotyping, and therefore were removed. Following this,  
179 2058 cores representing 1145 patients were included in our analysis.

180

## 181 **Spatial Pathology Analysis**

182 Using the cellular x,y coordinates and associated phenotype obtained from InForm quantitative  
183 pathology, each cell was used as starting points for radial spatial pathology. In pilot studies, we  
184 determined that cell-cell impacts could be best approximated by 22 $\mu$ m distance (approximately 2  
185 lymphocyte widths). The following code was developed in MatLab to identify, within 22 $\mu$ m  
186 distance, the fraction of cells of the core, that fit within each pre-defined neighborhood: Adaptive  
187 (at least one of each T cell, Mac and CD16a<sup>high</sup> NK cell, Neighborhood A), Innate (at least two  
188 CD16a<sup>low</sup> NK cell, Neighborhood B) or a General (any three immune cells, Neighborhood C).  
189 These neighborhoods, dictated by our co-infiltration studies, are described in additional detail  
190 below. The following coding strategy was used to identify how many cells fell within each of the  
191 three clusters.

192 We used a parameter  $R > 0$  to determine spatial proximity and define the following three types  
193 of regions:

194 `\begin(itemize)`

195 `\item Neighborhood A consists of those points of the image plane where at least one`  
196 `\texttt{CD68+ Macrophages) cell, one \texttt{CD16ahigh NK cells) and one \texttt{CD3+ T`  
197 `cells) are within a radius of  $R$ .`

198 `\item Neighborhood B consists of those points of the image plane where at least two`  
199 `\texttt{CD16alow NK cells) cells are within a radius of  $R$ .`

200 `\item Neighborhood C consists of those points of the image plane where at least three`  
201 `immune cells are within a radius of  $R$ , irrespective of their phenotype.`

202 `\end(itemize)`

203 In order to determine the fraction of immune cell neighborhoods in the \texttt{Stromal CD-} and  
204 \texttt{Epithelial CD-} regions, we create one two-dimensional map for each type of immune cell  
205 by adding binary valued radial basis functions of width  $R$  centred at each immune cell.  
206 Superimposing those maps according to the neighborhoods outlined above (A, B, C), enabled  
207 calculation of binary values reflecting whether or not the defined immune cell type exists within  
208 the same region. Two-dimensional interpolation allows querying those maps at the locations of all  
209 \texttt{Stromal CD-} and \texttt{Epithelial CD-} cells.

210

### 211 **Cell Lines**

212 Human cell lines used in flow cytometry assays included the HLA class I<sup>-</sup> K562 (American Type  
213 Culture Collection (ATCC)), and the ovarian cancer cell lines OVCAR4 (kindly provided by the  
214 laboratory of Dr. Barbara Vanderhyden) and OVCAR5. All cells were cultured at 37°C in 5% CO<sub>2</sub>  
215 in RPMI-1604 media with 10% heat inactivated FBS, 100 U/ml penicillin, and 100 mg/ml  
216 streptomycin sulfate.

217

### 218 **Flow Cytometry and Gating Strategy**

219 Isolated human PBMCs were stimulated using K562, OVCAR-4, and OVCAR-5 cells (3:1 ratio  
220 of PBMC:Target cell) for 5 hr in the presence of anti-CD107a (H4A3, BD Biosciences). Non-  
221 specific antibody binding was blocked by addition of 0.5 mg/mL human Fc block (BD  
222 Biosciences). Viable human NK cells were identified by excluding dead cells and gating for human  
223 CD56<sup>+</sup>CD3<sup>-</sup> cells (live/dead fixable dye, BD Biosciences). All antibodies, clones, and sources used  
224 to identify NK cell subsets are shown in supplementary table 3. Fluorescence was measured using

225 a BD FACS Symphony (BD Biosciences) and analysed using FlowJo 10 software (FlowJo LLC),  
226 gating strategy is noted in supplementary figure 4.

227

## 228 **Statistical Analysis**

229 GraphPad Prism 8 was used to generate all graphically visualized data. Specifically, Kaplan-Maier  
230 survival curves followed by log-rank testing were used to determine significant differences  
231 between various groups. High and low infiltrated tumors were defined based on median infiltration  
232 density of each immune cell (cells/mm<sup>2</sup>). Differences in infiltration numbers between groups  
233 categorized by clinical parameters were determined by one or two-way ANOVAs, as appropriate.  
234 To evaluate the co-infiltration between intratumoral immune cells or neighborhoods, a Pearson's  
235 correlation was conducted with all *r* values listed for each pair in the correlation matrix. The  
236 threshold for statistical significance was set at  $\alpha = 0.05$ ; however, non-statistical but clinically  
237 relevant associations, defined by the authors, were described along with corresponding *p* values.

238

239 **RESULTS**

240 **NK cells are frequently found within HGSC tumors and demonstrate superior ability to**  
241 **infiltrate IE regions compared to T cells and macrophages**

242 We developed a novel Opal multiplex IF panel to accurately identify and capture immune cell  
243 populations within HGSC tissues with a focus on NK cells. To circumvent the challenges  
244 associated with epithelial cell expression of CD56 that have been reported in ovarian cancer[21],  
245 we used a combination of CD94 and CD16a to capture both the CD16<sup>high</sup> and CD16<sup>low</sup> populations  
246 of NK cells, which were further defined as CD3<sup>-</sup>CD68<sup>-</sup> (Figure 1A). T cells and macrophages were  
247 defined as CD3<sup>+</sup>CD16<sup>-</sup>CD94<sup>+/-</sup> and CD68<sup>+</sup>CD16<sup>+/-</sup>CD94<sup>-</sup>, respectively. Staining and subsequent  
248 digital pathology, including tissue and cellular segmentation, was validated by TA. Automated  
249 tissue segmentation was highly concordant with manual pathology evaluation, while cellular  
250 segmentation was comparable. We found that InForm software slightly underreported (~84% of  
251 actual) cell counts in IE and overcounted (~108% of actual) in IS regions (Supplementary Figure  
252 2). We used this panel along with spectral unmixing and digital pathology to quantify the number  
253 of each immune cell population by HGSC core (Figure 1B).

254 CD16a<sup>high</sup> and CD16a<sup>low</sup> NK cells infiltrated 95% and 90% of HGSC cores, respectively.  
255 In agreement with previous studies[28, 29], we found the largest frequency of tumor infiltrating  
256 immune cells to be macrophages (median = 149 cells/mm<sup>2</sup>) followed by T cells (median = 130.5  
257 cells/mm<sup>2</sup>), while CD16a<sup>high</sup> NK cells (median = 60.35 cell/mm<sup>2</sup>) and CD16a<sup>low</sup> NK cells (median  
258 = 11.20 cell/mm<sup>2</sup>) infiltrated less frequently (Figure 1C). Although NK cells were represented at  
259 the lowest frequencies in both IS and IE regions, both CD16a<sup>high</sup> and CD16a<sup>low</sup> NK cells were  
260 overrepresented in IE regions, suggesting a preferential recruitment to engage with HGSC cells  
261 (p<0.05 compared with all other subsets; Figure 1D).

262 We next investigated how the frequency of immune cell infiltration associated with clinical  
263 parameters including patient age, *BRCA* status, tumor grade, tumor stage, and chemotherapy status  
264 (platinum-sensitive or resistant at 6 months post therapy) (Figure 2). There was no association  
265 between any immune cell infiltration in the IS or IE regions with *BRCA* or chemotherapy status,  
266 but significant associations were found with tumor stage and grade (Figure 2A,B). Patients with  
267 stage 4 HGSC exhibited higher CD16a<sup>high</sup> frequencies in the IS region than patients with stage 3  
268 HGSC (Figure 2C). Significantly more immune cells, including CD16a<sup>high</sup> and CD16a<sup>low</sup> NK cells,  
269 infiltrated grade 3 tumors compared with grade 2 tumors, in both the stromal and epithelial regions  
270 (Figure 2D). Similar significant increases in infiltration at higher grades were seen for IS T cells  
271 and macrophages, but no difference was observed in corresponding IE infiltrates (Figure 2D).

272

273 **IS CD16a<sup>high</sup> NK cells predict improved 5-year progression free survival; IS CD16a<sup>low</sup> NK**  
274 **cell predict poorer 5-year progression free survival**

275 We conducted Kaplan-Meier analyses on the total, IE or IS immune cell infiltration using the  
276 median cell number to divide patients into groups of “high” and “low” infiltration. In line with  
277 previous studies in HGSC [28, 29], total T cells or total macrophages, without consideration for  
278 specific phenotype or inference of function (i.e. cytotoxic or regulatory; M1/M2), demonstrated  
279 no association with survival (Figure 3A). Interestingly, NK cells infiltrating into the IS region  
280 demonstrated survival associations dependent on their phenotype. Patients with  $\geq 86$  CD16a<sup>high</sup> NK  
281 cells/mm<sup>2</sup> in the IS region trended toward improved 5-year progression free survival ( $p=0.12$ );  
282 those with  $\geq 19.5$  CD16a<sup>low</sup> NK cells/mm<sup>2</sup> exhibited significantly poorer 5-year progression free  
283 survival ( $p=0.028$ ) (Figure 3A). We reasoned that if the number of infiltrating NK cells predicted  
284 survival, then the top and bottom quartiles should be the most disparate with respect to their ability

285 to predict survival outcomes. Indeed, comparing the quartiles in this way further distinguished the  
286 impact of NK cell infiltration: individuals representing top-quartile CD16a<sup>high</sup> IS NK cell  
287 infiltration demonstrated significantly improved progression free survival compared to those with  
288 bottom-quartile CD16a<sup>high</sup> infiltration (p=0.0471, Figure 3B).

289

290 **T cells, macrophages, and CD16a<sup>high</sup> NK cells demonstrate shared patterns of co-infiltration,**  
291 **distinct from infiltrating CD16a<sup>low</sup> NK cells**

292 Co-infiltrating leukocytes can impact immune responses within HGSC tumors with influences on  
293 survival and treatment outcomes[30]. We next explored leukocyte co-infiltration into HGSC  
294 tumors generally, and within IS and IE tumor compartments. Most commonly, lymphocytes co-  
295 infiltrated the IE and IS with cells of the same subtype (T cells: r = 0.62; CD16a<sup>high</sup> NK cells: r =  
296 0.74; CD16a<sup>low</sup>NK cells: r = 0.48). The highest co-infiltration rates into the IS and IE regions were  
297 observed when comparing the values of infiltration of one lymphocyte type against itself:  
298 CD16a<sup>high</sup> NK cells (r = 0.74); T cells (r = 0.62); and CD16a<sup>low</sup> NK cells (r = 0.48) (Figure 4A).  
299 Macrophages, however, most commonly co-infiltrated with CD16a<sup>high</sup> NK cells; most noteworthy  
300 was the correlation between IS macrophages and IS CD16a<sup>high</sup> NK cells (r = 0.47) (Figure 4A).  
301 Interestingly, within each tumor compartment, co-infiltration between the two NK cell phenotypes  
302 was not frequently observed (IS; r= 0.31, IE; r= 0.22) (Figure 4A). In fact, co-infiltration between  
303 CD16a<sup>high</sup> NK cells and either T cells or macrophages was more likely than co-infiltration of  
304 CD16a<sup>high</sup> NK cells and CD16a<sup>low</sup> NK cells in both IS and IE regions. Co-infiltration of CD16a<sup>low</sup>  
305 NK cells and T cells and/or macrophages was rare in both regions. This indicates that tumors may  
306 exhibit patterns of infiltration that can be classified as “adaptive”, which consist of CD16a<sup>high</sup> NK

307 cells, T cells and macrophages or “innate” infiltrates which consists of CD16a<sup>low</sup> NK cells, with or  
308 without T cells and macrophages (Figure 4B).

309

### 310 **Spatial analysis reveals that adaptive immune infiltrates predict longer progression free** 311 **survival**

312 We next asked whether the adaptive or innate infiltrate patterns predicted patient outcomes and  
313 used spatial analysis to define cellular “neighborhoods”. These neighborhoods were quantified  
314 based on the proximity of defined immune cells at a maximum of 22 $\mu$ m away from each other  
315 (Figure 5). Each neighbourhood was defined as either adaptive (one T cell, macrophage and  
316 CD16a<sup>high</sup> NK cell), innate (two CD16a<sup>low</sup> NK cells with or without other immune cells) or general  
317 (any other combination of at least three immune cells) (Figure 5A). These neighborhoods were  
318 then quantified based on the fraction of cells within the core that fell within them (the area of the  
319 neighborhood). We asked whether the neighborhood composition of cores mattered. While almost  
320 every core (98.2%) had some proportion of cells falling within the general neighborhood, 70% and  
321 60% contained adaptive and innate neighborhoods, respectively (Figure 5B). When evaluating the  
322 prognostic potential of each, we observed that the frequency of general or innate cell  
323 neighborhoods did not associate significantly with progression free survival (Figure 5C). The  
324 presence of an adaptive neighborhood, however, was associated with a trend towards improved 5-  
325 year progression free survival ( $p = 0.069$ ) (Figure 5C).

326 We next tested whether different types of immune neighbourhoods are present within the  
327 same cores. We found that the area of both adaptive and general neighborhoods was correlated in  
328 both the IS ( $r = 0.74$ ) and IE ( $r = 0.70$ ) regions of the same core (Figure 5D). In contrast, the area  
329 of innate neighborhoods was not correlated with that of general neighborhoods in the IS ( $r = 0.22$ )

330 or IE ( $r = 0.23$ ) regions, or with the area of adaptive neighborhoods in the IS ( $r = 0.17$ ) or IE ( $r =$   
331  $0.12$ ). We conclude that immune cell infiltration is a general property of HGSC tumors, with  
332 skewing toward innate or adaptive phenotypes.

333 To determine whether the immunologic skewing might reflect tumor characteristics, we  
334 compared the immunologic phenotypes between patients based on tumor grade, stage, *BRCA* status  
335 and chemotherapy sensitivity. Both *BRCA1* and *BRCA2*-mutated tumors had significantly higher  
336 coverage by adaptive immune neighborhoods in the IE region (Figure 6A). While not statistically  
337 significant, we noted a trend toward higher coverage by innate neighborhoods in the IS region of  
338 chemotherapy resistant tumors ( $p = 0.074$ , Figure 6B). Similar to individual immune infiltration  
339 findings, we found a significant increase in the area covered by all immune neighborhoods in  
340 higher grade tumors (grade 3 vs. grade 2) (Figure 6D). Taken together, these findings suggest that  
341 the clinical or genetic characteristics of a tumor may predict its immune landscape.

342

### 343 **CD16<sup>high</sup> and CD16<sup>low</sup> NK cells are dichotomized by expression of CD39/CD73**

344 Our TMA analysis demonstrates that CD16<sup>high</sup> and CD16<sup>low</sup> NK cells have opposite associations  
345 with prognosis for patients with HGSC. To better understand the features of these two populations,  
346 we performed flow cytometry on PBMCs from six healthy donors challenged with ovarian cancer  
347 cell lines (OVCAR4 and OVCAR5) or the HLA-negative NK cell target, K562. We compared  
348 both populations for markers of activation and inhibition, as well as expression of CD39/73,  
349 exonucleosidases associated with degradation of ATP to adenosine, establishment of an  
350 immunosuppressive microenvironment in HGSC and regulatory NK cell function[31-33].  
351 Consistent with the missing self-responsiveness expected against an HLA-negative target cell, the  
352 greatest responsiveness against K562 cells was mediated by CD16<sup>bright</sup> NK cells (which are

353 enriched for the educated NK cell subset (Figure 7A). However, OVCAR4 and OVCAR5 cells,  
354 which persist in HLA expression, were targeted by both CD16a<sup>high</sup> and CD16a<sup>low</sup> subsets of NK  
355 cells.

356         Compared with responding CD16a<sup>dim</sup> NK cells, responding CD16a<sup>bright</sup> NK cells expressed  
357 higher NKp46 and NKG2D activating receptors, and the TIM-3 inhibitory receptor. Noteworthy,  
358 the responding CD16a<sup>dim</sup> population was consistently enriched for cells expressing CD39/CD73  
359 compared with the responding CD16<sup>bright</sup> population (Figure 7B – G), suggesting that the C16<sup>dim</sup>  
360 may have immune regulatory potential in the ATP/adenosine-rich tumor microenvironment.

361

## 362 DISCUSSION

363 To our knowledge, this is the most in-depth and specific exploration of NK cell infiltration into  
364 HGSC. Using a TMA that represented 1145 patients with HGSC, we have refined and expanded  
365 the predictive prognostic value of NK cell infiltration into HGSC tumors. Using multiplex IF, and  
366 pathologist-validated machine learning, we spatially resolved all cells with an NK cell phenotype,  
367 and differentiated subsets based on CD16a staining intensity. We report that both the subtype of  
368 NK cell and its localization within the TME contribute to prognostic associations for patients with  
369 HGSC. The biggest impacts of cellular infiltration on progression free survival were observed  
370 among NK cell subsets infiltrating the IS region: infiltration of CD16a<sup>low</sup> NK cells is associated  
371 with poor progression free survival; infiltration of CD16a<sup>high</sup> NK cells is associated with improved  
372 progression free survival. Using a correlational approach, we find that CD16a<sup>high</sup> NK cells co-  
373 infiltrate with T cells and macrophages; hence the presence of CD16<sup>high</sup> NK cells might predict for  
374 infiltration of a collection of immune cells that contribute to control of HGSC.

375 The function of NK cells, defined by co-expression of germline-encoded receptors, remains  
376 to be defined in HGSC, but the dichotomy of prognostic impacts that associate with CD16a  
377 phenotypes points to differential function among NK cell subsets[34]. Typically, CD16a<sup>high</sup> NK  
378 cells are the most frequent in the blood, have high cytotoxic function, KIR expression, education  
379 for missing self-reactivity and produce pro-inflammatory cytokines. CD16a<sup>low</sup> NK cells, by  
380 contrast, can take on an array of functions including cytokine production and immune  
381 regulation[16, 35]. Among this CD16<sup>low</sup> subset, we identified a high frequency of cells expressing  
382 CD39/73. These are ectonucleotidases associated with degradation of ATP to AMP, then ADO,  
383 and have been associated with immunoregulatory functions among NK and other immune  
384 cells[32]. High expression of CD73 and CD39 associates with the immunoregulatory subtype of

385 HGSC[32], and its associated poor prognosis[33]. CD39/73<sup>+</sup> NK cells were responsive in our *in*  
386 *vitro* analysis, but this was conducted in the absence of the immunosuppressive and adenosine-  
387 rich microenvironment of HGSC. For CD16a<sup>dim</sup>CD39/73<sup>+</sup> NK cells, the tumor microenvironment  
388 would be expected to provide signals for adenosine-mediated inhibition and potentially interrupt  
389 cytotoxic NK cell function. The function of CD16<sup>dim</sup>CD39/73<sup>+</sup> NK cells may be interrupted, or  
390 become immunoregulatory, in the tumor microenvironment, which may account for its association  
391 with relatively poorer outcomes for patients.

392         The impacts of tumour-infiltrating NK cells in HGSC are controversial, with studies  
393 alternately ascribing beneficial or detrimental roles. This may reflect the way that NK cells were  
394 appraised in these studies. In a recent meta-analysis, we demonstrated that studies across all solid  
395 tumors were more likely to identify a positive prognostic association of NK cells if they were  
396 stained using antibodies against CD56 or CD57 rather than NKp46[36]. CD56 staining is  
397 unreliable in HGSC because the tumor cells themselves frequently (~60%) express CD56[20].  
398 CD57 expression is likewise not ideal: though restricted to NK cells, it is selectively expressed on  
399 the CD56<sup>dim</sup>CD16a<sup>high</sup> population. Indeed, studies of HGSC that defined NK cells using CD57  
400 staining have defined a prognostic benefit of NK cell staining [24, 25]; likely, this reflected  
401 measurement the CD16<sup>high</sup> NK cell population. Staining with NKp46 would capture a broader  
402 population of NK cells, but also innate-like lymphocytes (ILCs), which are known to have  
403 immunosuppressive activity that interferes with immune-mediated tumor cell killing[37, 38]. To  
404 circumvent these challenges while specifically and completely marking NK cells, we stained for  
405 CD94 (a component of the binding complexes formed by the NK receptor group 2 (NKG2)  
406 receptors found on all NK cells, validating this approach using PBMC, tonsil samples and HGSC  
407 cores on which CD56 epithelial staining did not occur (data not shown).

408           An additional feature that allowed us to refine NK cell associations was our division of the  
409 IS and IE regions by including pancytokeratin staining in our multiplex panel[24, 25]. With this  
410 approach, we identified that NK cells are more likely to be recruited to the IE than T cells or  
411 macrophages, and that the prognostic benefit of CD16a<sup>high</sup> and detriment of CD16a<sup>low</sup> NK cells  
412 was associated with their frequency in the IS regions specifically. Within the IE, NK cells would  
413 be exposed to inhibitory ligands and checkpoints, including NKG2A[20]; nevertheless, the  
414 localization of NK cells to the epithelial region supports strategies to maximize NK cell reactivity  
415 or recruit these cells from the neighboring IS regions. For patients lacking CD16a<sup>high</sup> NK cells,  
416 strategies to inflame the tumor and induce an infiltration of leukocytes with anti-tumor function  
417 may be required to facilitate tumor control[39, 40]. Further, a key consideration is how tumour  
418 progression and treatment may influence the state of immunity within the TME. We have  
419 previously reviewed the many additional alterations found in NK cells isolated from ovarian cancer  
420 patient tumors and ascites elsewhere[41]. For example, NK cells isolated from the ascites of  
421 ovarian carcinoma patients had significantly decreased CD16a expression compared to that found  
422 in peripheral blood[42].

423           Conclusive functional studies are beyond the scope of this report, but our observations  
424 suggest that there is a setpoint for immunity that differs between patients with ovarian HGSC.  
425 Both CD16<sup>high</sup> and CD16<sup>low</sup> NK cells can be recruited to sites of infection or cancer by chemokines  
426 and influenced by local cytokines in the TME, which may differ between patients[39, 43]. We  
427 found that although the types of infiltrating NK cells were not mutually exclusive, the majority of  
428 tumor cores that we studied were preferentially infiltrated by one subtype. “Adaptive” immune  
429 cell neighborhoods, defined by the presence of CD16a<sup>high</sup> NK cells, T cells and macrophages, were  
430 most often found in cores with other adaptive and “general” immune cell neighborhoods, but not

431 with “innate” neighborhoods, which consisted of CD16a<sup>low</sup> NK cells. Innate neighborhoods, by  
432 contrast, were small or absent in cores with adaptive neighborhoods representing larger areas. We  
433 identified associations with clinical features: the presence of adaptive clusters was associated with  
434 *BRCA* mutations and higher-grade tumors, while the presence of innate clusters was associated  
435 with chemotherapy resistance. Our samples were all taken from treatment-naïve patients that went  
436 on to receive therapy. Perhaps the availability of CD16<sup>high</sup> NK cells, T cells and macrophages in  
437 patients with adaptive clusters fosters productive antitumor immunity by collaborating on key  
438 features such as direct immunogenic cell death facilitated by NK cell cytotoxicity, followed by  
439 antigen presentation and cytokine polarization[44]. Those with innate clusters, defined by  
440 CD16a<sup>low</sup> NK cells, may instead be associated with a more suppressive TME (i.e. TGF- $\beta$ , IL-10  
441 checkpoints, CD39/73 expression on NK and other cells[33]), and/or the lack of anti-tumor  
442 effector cells.

443 Ovarian HGSC tumors carry a high neoantigen burden, which has made them candidates  
444 for immunotherapy. However, checkpoint inhibition strategies have not impacted HGSC  
445 substantially [4-6], suggesting a failure of lymphocytes to completely recognize and control  
446 tumors. Indeed, sequencing of the TCRs of tumor-infiltrating T cells demonstrated that the  
447 majority do not have specificity for tumor antigens[45]. Moreover, HGSC progression, genomic  
448 instability and checkpoint therapy can promote outgrowth of mutants with loss-of-heterozygosity  
449 or disruption of components of the HLA processing and presentation pathway, which enables  
450 escape from T cell mediated (i.e. HLA-restricted) recognition[46, 47]. With these features in mind,  
451 the roles of infiltrating NK cells may be to initiate tumor killing via antigen-independent  
452 mechanisms, promote phagocytosis and presentation of neoantigens to prime T cells, and missing  
453 self-recognition and killing of HLA-negative tumors. These features are consistent with NK cells

454 expressing high levels of CD16a[16]. For this study, we chose to focus on NK cells and their  
455 localization within tumor regions. Limitations in the staining panel size meant that we were unable  
456 to study the function of macrophages (i.e. discern as suppressive M1 or pro-inflammatory M2) or  
457 T cells (as CD4, CD8, regulatory), but previous studies have revealed that infiltration of cytotoxic  
458 CD8<sup>+</sup> T cells or M1-polarized macrophages are independently associated with improved overall  
459 survival in patients with HGSC[48, 49]. Acting together with C16<sup>high</sup> NK cells, these anti-tumor  
460 leukocytes might best respond to the diverse array of phenotypes of HGSC cells that occur. Our  
461 current findings endorse strategies to recruit or active CD16a<sup>high</sup> NK cells in immunotherapies for  
462 HGSC. Future studies to clarify the key features, functions and interactions between NK cells and  
463 other leukocytes may inform immunotherapies to best recruit CD16<sup>high</sup> NK cells to maximize  
464 HGSC control.

465

466 **DECLARATIONS**

467 **Ethics**

468 All methods for specimens and clinical information collection and subsequent analyses were  
469 approved by Dalhousie University's Research Ethics Board (#2020-5060). Primary PBMC used  
470 to validate antibodies were approved by the Dalhousie University REB (#2016-3842) and the  
471 Canadian Blood Services REB (#2016-016).

472

473 **Consent for Publication**

474 All authors consent to publication of this work.

475

476 **Availability of data and material**

477 Aggregate clinical data is listed in supplementary table 1.

478 Quantitative pathological cell density and spatial pathology quantification by core is available  
479 upon request.

480

481 **Competing interests**

482 The authors declare that no competing interests exist.

483

484 **Author's Contributions**

485 The studies were conceptualized by SN, BHN and JEB; experiments were designed and validated  
486 by SN, SNL, SG, LM, LC, BHN, AMMM and JEB. Pathology review and validation of machine  
487 learning and analysis was conducted by SN and TA. Computational spatial analysis was designed  
488 by SN, DA and JEB, and conducted by DA. Flow cytometry and functional analysis was conducted

489 by SNL. The manuscript was written by SN, SG and JEB, reviewed, edited, and approved by all  
490 authors.

491

## 492 **Funding**

493 This work was supported by a Terry Fox Research Institute New Investigator Award with the pan-  
494 Canadian ImmunoTherapeutic NeTwork (iTNT) and a Canadian Foundation for Innovation award  
495 to JEB. JEB is the Dalhousie Faculty of Medicine / Dalhousie Medical Research Foundation  
496 Cameron Cancer Scientist. SN is supported by a Vanier Scholarship through CIHR, Cancer  
497 Research Training Program of the Beatrice Hunter Cancer Research Institute, Nova Scotia  
498 Graduate Scholarship, Killam Scholarship, and a President's Award through Dalhousie University.  
499 SL is supported by Nova Scotia Graduate Scholarship, a Dalhousie Faculty of Medicine-Dalhousie  
500 Medical Research Foundation 2020 I3V Graduate Studentship, a Canadian Graduate Scholarship  
501 through CIHR, and Cancer Research Training Program of the Beatrice Hunter Cancer Research  
502 Institute cofunded by Craig's Cause Pancreatic Cancer Society. SRG is funded by the Beatrice  
503 Hunter Cancer Research Institute through the IWK Foundation Jeremy Ingham Summer  
504 Studentship.

505

## 506 **Acknowledgements**

507 The authors gratefully acknowledge experimental assistance from Ms. Morgan Pugh-Toole and  
508 Katy Milne, and PBMCs provided in collaboration with Canadian Blood Services. This study uses  
509 resources provided by the Canadian Ovarian Cancer Research Consortium's - COEUR biobank  
510 funded by the Terry Fox Research Institute and Ovarian Cancer Canada and managed and  
511 supervised by the Centre de recherche du Centre hospitalier de l'Université de Montréal

512 (CRCHUM). The Consortium acknowledges contributions to its COEUR biobank from  
513 Institutions across Canada (for a full list see [www.tfri.ca/COEUR/members](http://www.tfri.ca/COEUR/members)).

514

#### 515 **List of Abbreviations**

516 COEUR: The Canadian Ovarian Experimental Unified Resource

517 FFPE: formalin-fixed paraffin-embedded

518 HGSC: high grade serous carcinoma

519 IE: Intraepithelial

520 IS: Intrastromal

521 HLA: human leukocyte antigen

522 NK: natural killer

523 PBMC: peripheral blood mononuclear cells

524 TME: tumour microenvironment

525

## 526 REFERENCES


- 527 1. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities  
528 for translation. *Nat Rev Cancer*. 2009;9(6):415-28.
- 529 2. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian  
530 cancer statistics, 2018. *CA Cancer J Clin*. 2018;68(4):284-96.
- 531 3. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of  
532 Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined  
533 Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the  
534 Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-  
535 OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire  
536 (GINECO). *Cancer-Am Cancer Soc*. 2009;115(6):1234-44.
- 537 4. Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, et al. An interim  
538 report on the investigator-initiated phase 2 study of pembrolizumab immunological response  
539 evaluation (INSPIRE). *J Immunother Cancer*. 2019;7(1):72.
- 540 5. Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et  
541 al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian  
542 cancer: results from the phase II KEYNOTE-100 study. *Ann Oncol*. 2019;30(7):1080-7.
- 543 6. Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, et al.  
544 Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer:  
545 Analysis of KEYNOTE-028. *Gynecol Oncol*. 2019;152(2):243-50.
- 546 7. Chen P, Zhang Q, Shen L, Li R, Tan C, Chen T, et al. Insights into the synergetic  
547 mechanism of a combined vis-RGO/TiO<sub>2</sub>/peroxodisulfate system for the degradation of PPCPs:  
548 Kinetics, environmental factors and products. *Chemosphere*. 2019;216:341-51.
- 549 8. Jimenez-Sanchez A, Cybulska P, Mager KL, Koplev S, Cast O, Couturier DL, et al.  
550 Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic  
551 effect of chemotherapy. *Nat Genet*. 2020;52(6):582-93.
- 552 9. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient  
553 lymphoma variants suggests alternative immune defence strategy. *Nature*. 1986;319(6055):675-  
554 8.
- 555 10. Kannan GS, Aquino-Lopez A, Lee DA. Natural killer cells in malignant hematology: A  
556 primer for the non-immunologist. *Blood Rev*. 2017;31(2):1-10.
- 557 11. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development,  
558 Maturation, and Clinical Utilization. *Front Immunol*. 2018;9:1869.
- 559 12. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse  
560 lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. *Int*  
561 *J Cancer*. 1975;16(2):230-9.
- 562 13. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, et al. Human  
563 natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. *Blood*.  
564 2001;97(10):3146-51.
- 565 14. Martinez-Lostao L, Anel A, Pardo J. How Do Cytotoxic Lymphocytes Kill Cancer Cells?  
566 *Clinical Cancer Research*. 2015;21(22):5047-56.
- 567 15. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC, et al.  
568 Genetic and environmental determinants of human NK cell diversity revealed by mass  
569 cytometry. *Sci Transl Med*. 2013;5(208):208ra145.

- 570 16. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell  
571 subsets. *Trends in Immunology*. 2001;22(11):633-40.
- 572 17. Boudreau JE, Hsu KC. Natural Killer Cell Education and the Response to Infection and  
573 Cancer Therapy: Stay Tuned. *Trends Immunol*. 2018;39(3):222-39.
- 574 18. Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, et al. Clinical  
575 significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of  
576 ULBP2 is an indicator of poor prognosis. *Cancer Immunol Immunother*. 2009;58(5):641-52.
- 577 19. Henriksen JR, Donskov F, Waldstrom M, Jakobsen A, Hjortkjaer M, Petersen CB, et al.  
578 Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian  
579 carcinoma. *Acta Oncol*. 2020:1-8.
- 580 20. Katou F, Ohtani H, Watanabe Y, Nakayama T, Yoshie O, Hashimoto K. Differing  
581 phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer.  
582 *Cancer Res*. 2007;67(23):11195-201.
- 583 21. Bosmuller HC, Wagner P, Pham DL, Fischer AK, Greif K, Beschorner C, et al. CD56  
584 (Neural Cell Adhesion Molecule) Expression in Ovarian Carcinomas: Association With High-  
585 Grade and Advanced Stage But Not With Neuroendocrine Differentiation. *Int J Gynecol Cancer*.  
586 2017;27(2):239-45.
- 587 22. Henriksen JR, Donskov F, Waldstrom M, Jakobsen A, Hjortkjaer M, Petersen CB, et al.  
588 Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian  
589 carcinoma. *Acta Oncol*. 2020;59(6):652-9.
- 590 23. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al.  
591 CD57 defines a functionally distinct population of mature NK cells in the human  
592 CD56dimCD16+ NK-cell subset. *Blood*. 2010;116(19):3865-74.
- 593 24. Vetter CS, Straten PT, Terheyden P, Zeuthen J, Brocker EB, Becker JC. Expression of  
594 CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma. *J*  
595 *Invest Dermatol*. 2000;114(5):941-7.
- 596 25. Pulford KA, Sipos A, Cordell JL, Stross WP, Mason DY. Distribution of the CD68  
597 macrophage/myeloid associated antigen. *Int Immunol*. 1990;2(10):973-80.
- 598 26. Le Page C, Rahimi K, Kobel M, Tonin PN, Meunier L, Portelance L, et al.  
599 Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer  
600 biomarkers. *BMC Cancer*. 2018;18(1):347.
- 601 27. Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, et al. The Society  
602 for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry  
603 (IHC) and immunofluorescence (IF) staining and validation. *J Immunother Cancer*. 2020;8(1).
- 604 28. Liu R, Hu R, Zeng Y, Zhang W, Zhou HH. Tumour immune cell infiltration and survival  
605 after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene  
606 expression-based computational study. *EBioMedicine*. 2020;51:102602.
- 607 29. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, et al. Molecular Analysis of  
608 Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. *Cell Rep*. 2020;31(2):107502.
- 609 30. Montfort A, Owen S, Piskorz AM, Supernat A, Moore L, Al-Khalidi S, et al. Combining  
610 measures of immune infiltration shows additive effect on survival prediction in high-grade  
611 serous ovarian carcinoma. *Br J Cancer*. 2020;122(12):1803-10.
- 612 31. Chambers AM, Wang J, Lupo KB, Yu H, Atallah Lanman NM, Matosevic S.  
613 Adenosinergic Signaling Alters Natural Killer Cell Functional Responses. *Front Immunol*.  
614 2018;9:2533.

- 615 32. Bareche Y, Pommey S, Carneiro M, Buisseret L, Cousineau I, Thebault P, et al. High-  
616 dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer. *J*  
617 *Immunother Cancer*. 2021;9(3).
- 618 33. Gaudreau PO, Allard B, Turcotte M, Stagg J. CD73-adenosine reduces immune  
619 responses and survival in ovarian cancer patients. *Oncoimmunology*. 2016;5(5):e1127496.
- 620 34. Stabile H, Fionda C, Gismondi A, Santoni A. Role of Distinct Natural Killer Cell Subsets  
621 in Anticancer Response. *Front Immunol*. 2017;8:293.
- 622 35. Cooper MA. Human natural killer cells: a unique innate immunoregulatory role for the  
623 CD56bright subset. *Blood*. 2001;97(10):3146-51.
- 624 36. Nersesian S, Schwartz SL, Grantham SR, MacLean LK, Lee SN, Pugh-Toole M, et al.  
625 NK cell infiltration is associated with improved overall survival in solid cancers: A systematic  
626 review and meta-analysis. *Transl Oncol*. 2021;14(1):100930.
- 627 37. Nagasawa M, Heesters BA, Kradolfer CMA, Krabbendam L, Martinez-Gonzalez I, de  
628 Bruijn MJW, et al. KLRG1 and NKp46 discriminate subpopulations of human  
629 CD117(+)CRTH2(-) ILCs biased toward ILC2 or ILC3. *J Exp Med*. 2019;216(8):1762-76.
- 630 38. Crome SQ, Nguyen LT, Lopez-Verges S, Yang SY, Martin B, Yam JY, et al. A distinct  
631 innate lymphoid cell population regulates tumor-associated T cells. *Nat Med*. 2017;23(3):368-75.
- 632 39. Castriconi R, Carrega P, Dondero A, Bellora F, Casu B, Regis S, et al. Molecular  
633 Mechanisms Directing Migration and Retention of Natural Killer Cells in Human Tissues. *Front*  
634 *Immunol*. 2018;9:2324.
- 635 40. Susek KH, Karvouni M, Alici E, Lundqvist A. The Role of CXC Chemokine Receptors  
636 1-4 on Immune Cells in the Tumor Microenvironment. *Front Immunol*. 2018;9:2159.
- 637 41. Nersesian S, Glazebrook H, Toulany J, Grantham SR, Boudreau JE. Naturally Killing the  
638 Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. *Front Immunol*.  
639 2019;10:1782.
- 640 42. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL.  
641 Alterations in expression and function of signal-transducing proteins in tumor-associated T and  
642 natural killer cells in patients with ovarian carcinoma. *Clin Cancer Res*. 1996;2(1):161-73.
- 643 43. Gaggero S, Witt K, Carlsten M, Mitra S. Cytokines Orchestrating the Natural Killer-  
644 Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-  
645 Based Cancer Immunotherapy. *Front Immunol*. 2020;11:621225.
- 646 44. Minute L, Teijeira A, Sanchez-Paulete AR, Ochoa MC, Alvarez M, Otano I, et al.  
647 Cellular cytotoxicity is a form of immunogenic cell death. *J Immunother Cancer*. 2020;8(1).
- 648 45. Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, et al. Surveillance of  
649 the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.  
650 *Clin Cancer Res*. 2014;20(5):1125-34.
- 651 46. Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, et al.  
652 Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-  
653 inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade  
654 serous ovarian carcinoma. *J Immunother Cancer*. 2020;8(1).
- 655 47. Montesion M, Murugesan K, Jin DX, Sharaf R, Sanchez N, Guria A, et al. Somatic HLA  
656 Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor  
657 Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. *Cancer Discov*.  
658 2021;11(2):282-92.


- 659 48. Webb JR, Milne K, Nelson BH. Location, location, location: CD103 demarcates  
660 intraepithelial, prognostically favorable CD8(+) tumor-infiltrating lymphocytes in ovarian  
661 cancer. *Oncoimmunology*. 2014;3:e27668.
- 662 49. Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, et al. A high M1/M2 ratio of tumor-  
663 associated macrophages is associated with extended survival in ovarian cancer patients. *J*  
664 *Ovarian Res*. 2014;7:19.
- 665

666 **FIGURES**




667

668 **Figure 1: Identification and quantification of NK cells, T cells and macrophages in HGSC**  
 669 **TMA by custom OPAL multiplex IF panel reveals preferential recruitment of CD16a<sup>high</sup> NK**  
 670 **cells to the epithelial region.** A) Representative pathology views of each individual marker in our TMA:  
 671 CD16a, CD3, CD68, CD94 and pancytokeratin (panCk) for a non-immune infiltrated, IS infiltrated and IE  
 672 infiltrated tumor cores; and B) corresponding multiplex overlay (left: anti-CD16a (green), anti-CD3 (red),  
 673 anti-CD68 (light blue), anti-CD94 (yellow), anti-panCk (pink) and DAPI (dark blue)), with phenotyping  
 674 map (right: stromal cell (gray), epithelial cell (maroon), T cell (red), Macrophage (blue), CD16a<sup>high</sup> NK cell  
 675 (orange), CD16a<sup>low</sup> NK cell (yellow)). C) Violin plots, with median noted by the solid line, demonstrate the  
 676 total range of cell density, as a measure of cell count over area (cells/mm<sup>2</sup>) by tumor compartment (IS vs.  
 677 IE). D) Violin plots representing the % cell density infiltrating the IE region / the total infiltration for each  
 678 tumor core, representing the specific cell subtypes indicated. Statistically significant p-values are noted atop  
 679 each pair-wise comparison determined by one-way ANOVA. \*, p<0.05; \*\*\*\*, p<0.001.




680

681 **Figure 2: Immune cell infiltration into HGSC tumors stratified by BRCA status, grade, stage**  
 682 **or chemosensitivity status.** Cell density of each immune population in the intrastromal (IS) vs.  
 683 intraepithelial (IE) tumor region stratified by A) BRCA status, B) chemotherapy status at 6 months C)  
 684 tumor stage or D) tumor grade. E) Heat map visualizing infiltration by cell density of both NK cell  
 685 populations, CD16a<sup>high</sup> and CD16a<sup>low</sup>, in Grade 2 or Grade 3 HGSC tumors. Statistically significant p-values  
 686 are noted atop each pair-wise comparison by cell type determined by either one-way ANOVA (3 or more  
 687 comparisons BRCA status and tumor stage) or t-test (2 comparisons, tumor grade). \*, p<0.05.




688

689 **Figure 3: Kaplan-Meier survival curves for HGSC infiltration of total, IS and IE immune**  
 690 **cells.** A) The median density of immune cell infiltrates ( $\text{cells}/\text{mm}^2$ ) were used to dichotomize  
 691 populations into either high or low immune infiltrate groups. Each immune cell population was  
 692 assessed by infiltration to the tumor, or specifically to the IS or IE regions. B) To further investigate  
 693 the benefit of CD16<sup>high</sup> NK cell infiltration, the population was broken into quartiles. Here the  
 694 lowest and highest quartile were compared by Kaplan-Meier survival. Survival curves are  
 695 surrounded by their 95% confidence intervals, with statistical significance tested by log-rank  
 696 method.




697  
 698 **Figure 4: Co-infiltration between total, IS and IE immune cells demonstrates two**  
 699 **independent patterns of immune cell infiltration: “adaptive” consisting of CD16a<sup>high</sup> NK**  
 700 **cells, T cells and macrophages, and “innate” consisting of CD16a<sup>low</sup> NK cells. A) Pearson’s**  
 701 **correlation matrix identifying co-infiltration of specific immune populations into each tumor**  
 702 **region; IS and IE. B) Visualization demonstrating the relationship between infiltrating immune**  
 703 **populations in and between each tumor regions. The Pearson’s correlation values are**  
 704 **represented as the lines between immune cell populations, with thickness of the lines representing**  
 705 **the strength of those co-infiltration values. C) Heat map of 100 randomly selected, representative**  
 706 **tumor cores with intrastromal and intraepithelial densities of each immune phenotype.**




707

708 **Figure 5: Adaptive immune neighborhoods of macrophages, T cells and CD16a<sup>high</sup> NK cells**  
 709 **predict longer progression free survival.** A) Coordinates of each immune cell phenotype,  
 710 identified by quantitative pathology, were imported to MatLab. Thereafter, cellular neighborhoods  
 711 were identified by proximity at a maximum of 22 $\mu$ m distances. Neighborhoods were classified as  
 712 adaptive immune (macrophages, T cells and CD16a<sup>high</sup> NK cells), innate immune (a minimum of  
 713 two CD16a<sup>low</sup> NK cells), or general immune (any three immune cells). B) Superimposed bar graph  
 714 and violin plot depict the frequency and distribution of fraction of cells covered by general,  
 715 adaptive or innate neighborhoods. C) Immune cell neighborhoods were dichotomized above or  
 716 below the median by either high vs low (general immune) or by the presence or absence of immune  
 717 neighborhoods (adaptive or innate immunity). Differences in survival between groups was  
 718 statistically evaluated by log-rank test. D) Pearson's R correlation matrix of immune  
 719 neighborhoods infiltrating within cores by tumor location



720  
 721 **Figure 6: Adaptive immune neighborhoods are found at a higher frequency in BRCA1/2**  
 722 **mutated tumors, while innate neighborhoods are found in higher frequency in**  
 723 **chemoresistant tumors. A) Cell density of each immune population in the IS vs. IE tumoral**  
 724 **region stratified by BRCA status. B) chemotherapy status at 6 months C) tumor stage or D) tumor**  
 725 **grade. Statistically significant p-values are noted atop each pair-wise comparison by cell type**  
 726 **determined by either one-way ANOVA (3 or more comparisons BRCA status and tumor stage) or**  
 727 **t-test (2 comparisons, tumor grade). \*, p<0.05.**



728  
 729 **Figure 7: CD16<sup>high</sup> NK cells demonstrate a phenotype consistent with immunoregulation.**  
 730 Flow cytometry analysis was conducted on NK cells co-cultured with K562, OVCAR4 and  
 731 OVCAR5 cell lines. A) The percent of responding NK cells in each co-culture comparing CD16<sup>high</sup>  
 732 to CD16<sup>low</sup> NK cells. Lines join populations from each independent donor. B) t-SNE representation  
 733 of CD56, CD16 and CD39/CD73 from the combined NK cell populations responding to target cell  
 734 stimulation, or NK cell populations responding against OVCAR4 and OVCAR5 cells. C)  
 735 Percentage of total or responding NK cell populations positive for phenotypic markers NKG2D,  
 736 NKp46, TIM-3, NKG2A and CD39/73 of NK cells from each donor (represented by an individual  
 737 dot with CD16<sup>high</sup> and CD16<sup>low</sup> NK cells from the same donor joined by a line) and those  
 738 responding in co-cultures with D) OVCAR4 or E) OVCAR5 cell lines. Histograms illustrating  
 739 CD39/CD73 expression of responding NK cell population against F) OVCAR4 and G) OVCAR5  
 740 cell lines and H) corresponding MFI quantification. Statistically significant p-values are noted atop  
 741 each pair-wise comparison by cell type determined by paired t-tests. \*\*\*\*, p<0.001 (OVCAR4).